Chinese government okays Sumitomo investment

After 16 months of wrangling, Japanese investor secures 20% in Henan Topfond Pharmaceutical.

Sumitomo, one of JapanÆs largest trading corporations, announced yesterday March 13 that it has completed the acquisition of a strategic interest in a profitable Chinese drug-maker. The deal will enable Sumitomo, which also recently acquired a Japanese drug maker, to expand its presence in China, and to source Henan TopfondÆs range of generic drugs for sales abroad.

The deal represents the first such strategic stake in a Chinese company by Sumitomo, which has previously been restricted to joint ventures. Although...

To continue reading, please login or register for free

Click for more on: china | japan | tofond | sumitomo

Print Edition

FinanceAsia Print Edition

CONFERENCES

  • Green Bonds Southeast Asia

    25 May 2017  |  Singapore
    With Green Bonds globally reaching USD200 billion outstanding in 2016, from as little as 30bn just 4 years ago, can SE Asia corporations and ...
  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...